日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Outcomes of Brentuximab Vedotin Monotherapy in Refractory/Relapsed Classical Hodgkin's Lymphoma: A Multi-Center Retrospective Study on Survival and Safety

布伦妥昔单抗单药治疗难治性/复发性经典型霍奇金淋巴瘤的疗效:一项多中心回顾性生存和安全性研究

Bakirtas, Mehmet; Hindilerden, Ipek Yonal; Ulu, Bahar Uncu; Ekinci, Omer; Dogu, Mehmet Hilmi; Aydogdu, Ismet; Berber, Ilhami; Ozatli, Duzgun; Demircioglu, Sinan; Cagliyan, Gulsum Akgun; Namdaroglu, Sinem; Tiryaki, Tarik Onur; Yigenoglu, Tugce Nur; Serin, Istemi; Turgut, Burhan; Albayrak, Murat; Katircilar, Yavuz; Hacıbekiroglu, Tuba; Nalcaci, Meliha; Erkurt, Mehmet Ali; Dal, Mehmet Sinan; Korkmaz, Serdal; Ulas, Turgay; Altuntas, Fevzi

Anti-T lymphocyte globulin plus posttransplant cyclophosphamide 25 mg/kg versus posttransplant cyclophosphamide 50 mg/kg in patients with acute leukemias

抗T淋巴细胞球蛋白联合移植后环磷酰胺25 mg/kg与移植后环磷酰胺50 mg/kg治疗急性白血病患者的疗效比较

Karakus, Abdullah; Toptas, Tayfur; Dal, Mehmet Sinan; Durdu, Ali; Hatipoglu, Ugur; Kayer, Merve Apaydin; Hindilerden, Ipek Yonal; Tiryaki, Tarik Onur; Iskender, Dicle; Ulu, Bahar Uncu; Yigenoglu, Tugce Nur; Erkurt, Mehmet Ali; Ulas, Turgay; Altuntas, Fevzi

The outcome of COVID-19 in patients with hematological malignancy

COVID-19 对血液系统恶性肿瘤患者的预后

Yigenoglu, Tugce N; Ata, Naim; Altuntas, Fevzi; Bascı, Semih; Dal, Mehmet Sinan; Korkmaz, Serdal; Namdaroglu, Sinem; Basturk, Abdulkadir; Hacıbekiroglu, Tuba; Dogu, Mehmet H; Berber, İlhami; Dal, Kursat; Erkurt, Mehmet A; Turgut, Burhan; Ulgu, Mustafa Mahir; Celik, Osman; Imrat, Ersan; Birinci, Suayip

The outcome ofancy. COVID-19 in patients with hematological malign

癌症的结局。COVID-19 在血液系统恶性肿瘤患者中的发生率

Yigenoglu, Tugce N; Bascı, Semih; Dal, Mehmet S; Korkmaz, Serdal; Turgut, Burhan; Altuntas, Fevzi